West Pharmaceutical Services, I
WST
Positions held
Your positionsWST isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- West Pharmaceutical Services operates in a growing healthcare sector, focusing on innovative medical instruments and supplies that are essential for drug delivery and patient care.
- Revenue increased by 3% compared to the prior quarter, reaching $872 million.
- Gross margin improved to 37.7%, up from 35.1% in the previous quarter.
- Despite strong growth, West Pharmaceutical Services has a high trailing P/E ratio of 47.71, which may indicate overvaluation compared to industry peers.
- The debt-to-equity ratio stands at 10.585, suggesting significant leverage that could pose risks in a downturn.
- The forward P/E ratio is 37.34, indicating expectations of slower earnings growth in the near future.
Fundamentals
| Market cap | $25.57B | Enterprise value | $25.45B | Trailing P/E | 46.51 | Forward P/E | 36.35 |
| PEG | 2.85 | Price / book | 8.55 | Beta | 1.13 | Dividend yield | 0.24% |
| Revenue growth | 13.8% | Earnings growth | 18.1% | Gross margin | 36.8% | Operating margin | 22.5% |
| Profit margin | 17.0% | ROE | 19.1% | ROA | 11.4% | Debt / equity | 0.11 |
| Current ratio | 2.82 | Free cash flow | $277.94M | Analyst recommendation | strong_buy | Mean target | $412.25 |
| 52w high | $386.00 | 52w low | $223.83 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $872M | $845M | $805M | $805M | $767M | — |
| Op margin | 22.0% | 21.4% | 21.8% | 21.7% | 20.7% | — |
| Net income | $154M | $139M | $132M | $140M | $132M | — |
| Gross margin | 37.7% | 35.1% | 37.8% | 36.6% | 35.7% | — |
| Gross profit | $329M | $296M | $304M | $294M | $274M | — |
| Operating income | $192M | $181M | $175M | $175M | $159M | — |
- Revenue +3% vs prior quarter ($872M vs $845M).
- Gross margin 37.7% (was 35.1% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.1B | $2.9B | $2.9B | $2.9B | — |
| Op margin | 20.7% | 20.4% | 24.0% | 26.4% | — |
| Net income | $494M | $493M | $593M | $586M | — |
| Gross margin | 35.9% | 34.5% | 38.3% | 39.4% | — |
| Gross profit | $1.1B | $999M | $1.1B | $1.1B | — |
| Operating income | $636M | $591M | $707M | $761M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
2026-10-09 · Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
2026-10-08 · Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
2026-10-08 · Here's Why You Should Retain WAT Stock in Your Portfolio for Now
2026-10-08 · West to Host Third-Quarter 2026 Conference Call
2026-10-08 · West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short
2026-10-07 · Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
2026-10-07 · Evercore ISI Adjusts West Pharmaceutical Services Price Target to $440 From $410
2026-10-07 · BDX Expands U.S. Manufacturing With $19B Healthcare Investment
2026-10-07 · Reasons to Hold HealthEquity Stock in Your Portfolio for Now
2026-10-07 · Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
2026-10-06 · Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
Price (daily)
Full chart · RSI · MACD · patterns